|Bid||63.00 x N/A|
|Ask||64.50 x N/A|
|Day's range||62.00 - 62.00|
|52-week range||51.81 - 79.50|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||20.06|
|Forward dividend & yield||0.11 (0.18%)|
|Ex-dividend date||19 Oct 2023|
|1y target est||N/A|
CHICAGO, November 29, 2023--GE HealthCare is proud to announce the addition of True Enhance DL to its Effortless Recon DL portfolio.
CHICAGO, November 28, 2023--Today GE HealthCare (Nasdaq: GEHC) announced an industry-first US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax (PTX) algorithm for the detection, notification, triage and diagnosis of PTX. The updated PTX algorithm expands Critical Care Suite’s on-device triage capabilities by providing immediate notification of the presence or absence of pneumothorax, as well as an overlay display both on-device and in PACS to assist with PTX localization.
CHICAGO, November 27, 2023--GE HealthCare announces new AI platform to support clinicians with breast cancer detection, improved workflow productivity - MyBreastAI Suite.